What did we learn on host's genetics by studying large cohorts of HIV-1-infected patients in the genome-wide association era?

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 290-296

  Guergnon, Julien ^a   Theodorou, Ioannis ^a,b  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

deep sequencing; genome wide association studies; hepatitis C virus; HIV

Indexed keywords

HLA B ANTIGEN; HLA C ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; DISEASE COURSE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPE; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

COHORT STUDIES; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 79959352468     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283478449     Document Type: Review

References (54)

1. Donfack J, Buchinsky FJ, Post JC, Ehrlich GD. Human susceptibility to viral infection: the search for HIV-protective alleles among Africans by means of genome-wide studies. AIDS Res Hum Retroviruses 2006; 22:925-930. (Pubitemid 46100675)
2. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947. (Pubitemid 47301321)
3. Fellay J. Host genetics influences on HIV type-1 disease. Antivir Ther 2009; 14:731-738.
4. Dalmasso C, Carpentier W, Meyer L, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 2008; 3:e3907.
5. Limou S, Le Clerc S, Coulonges C, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199:419-426.
6. Fellay J, Ge D, Shianna KV, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
7. Le Clerc S, Limou S, Coulonges C, et al. Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). J Infect Dis 2009; 200:1194-1201.
8. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557. A study that shows the importance to gather data from a big number of patients for providing a functional interpretation of genetic data.
9. Catano G, Kulkarni H, He W, et al. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One 2008; 3:e3636.
10. Limou S, Coulonges C, Herbeck JT, et al. Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J Infect Dis 2010; 202:908-915. An interesting iconoclastic study that shows the importance of interpretation of statistical evidence.
11. Pontillo A, Brandao LA, Guimaraes RL, et al. A 30 UTR SNP in NLRP3 gene is associated with susceptibility to HIV-1 infection. J Acquir Immune Defic Syndr 2010; 54:236-240.
12. Ricci E, Malacrida S, Zanchetta M, et al. Toll-like receptor 9 polymorphisms influence mother-to-child transmission of human immunodeficiency virus type 1. J Transl Med 2010; 8:49-54.
13. Bhattacharya T, Stanton J, Kim EY, et al. CCL3L1 and HIV/AIDS susceptibility. Nat Med 2009; 15:1112-1115.
14. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862. (Pubitemid 26322495)
15. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-1243. (Pubitemid 26375409)
16. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282:1907-1911.
17. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277:959-965. (Pubitemid 27366682)
18. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 30A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-795.
19. Hendel H, Caillat-Zucman S, Lebuanec H, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999; 162:6942-6946. (Pubitemid 29309424)
20. Flores-Villanueva PO, Hendel H, Caillat-Zucman S, et al. Associations ofMHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J Immunol 2003; 170:1925-1929. (Pubitemid 36197411)
21. Kosmrlj A, Read EL, Qi Y, et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010; 465:350-354.
22. Couzin J. Genomics. Consensus emerges on HapMap strategy. Science 2004; 304:671-673.
23. Bonnet F, Morlat P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France. HIV Med 2002; 3:195-199.
24. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
25. Gandhi M, Benet LZ, Bacchetti P, et al. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009; 50:482-491.
26. Strickler HD, Fazzari M, Kovacs A, et al. Associations of insulin-like growth factor (IGF)-I and IGF-binding protein-3 with HIV disease progression in women. J Infect Dis 2008; 197:319-327. (Pubitemid 351263454)
27. Pelak K, Goldstein DB, Walley NM, et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010; 201:1141-1149.
28. Ngo-Giang-Huong N, Deveau C, Da Silva I, et al. Proviral HIV-1DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15:665-673. (Pubitemid 32423213)
29. Hosono K, Sasaki T, Minoshima S, Shimizu N. Identification and characterization of a novel gene family YPEL in a wide spectrum of eukaryotic species. Gene 2004; 340:31-43. (Pubitemid 39360230)
30. Xu J, Wu H, Zhang C, et al. Identification of a novel human DDX40gene, a new member of the DEAH-box protein family. J Hum Genet 2002; 47:681-683. (Pubitemid 36083252)
31. Jeang KT, Yedavalli V. Role of RNA helicases in HIV-1 replication. Nucleic Acids Res 2006; 34:4198-4205. (Pubitemid 44542199)
32. Grabar S, Selinger-Leneman H, Abgrall S, et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23:1163-1169.
33. Furumatsu T, Tsuda M, Taniguchi N, et al. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 2005; 280:8343-8350. (Pubitemid 40349737)
34. Ikeda T, Kawaguchi H, Kamekura S, et al. Distinct roles of Sox5, Sox6, and Sox9 in different stages of chondrogenic differentiation. J Bone Miner Metab 2005; 23:337-340. (Pubitemid 41223795)
35. Kiefer HL, Hanley TM, Marcello JE, et al. Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter. Uncoupling of histone acetylation and chromatin remodeling. J Biol Chem 2004; 279:43604-43613. (Pubitemid 39390663)
36. Maeda Y, Yamaguchi T, Hijikata Y, et al. All-trans retinoic acid attacks reverse transcriptase resulting in inhibition of HIV-1 replication. Hematology 2007; 12:263-266. (Pubitemid 46930256)
37. Invernizzi CF, Xie B, Richard S, Wainberg MA. PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA. Retrovirology 2006; 3:93-108.
38. Xie B, Invernizzi CF, Richard S, Wainberg MA. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat interactions with both cyclin T1 and the Tat transactivation region. J Virol 2007; 81:4226-4234. (Pubitemid 46586916)
39. Joubert BR, Lange EM, Franceschini N, et al. A whole genome association study of mother-to-child transmission of HIV in Malawi. Genome Med 2010; 2:17-28.
40. Kraan MC, Patel DD, Haringman JJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res 2001; 3:65-71. (Pubitemid 32223807)
41. Silvestri M, Bontempelli M, Giacomelli M, et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation? Clin Exp Allergy 2006; 36:1373-1381.
42. Weller JI, Song JZ, Heyen DW, et al. A new approach to the problem of multiple comparisons in the genetic dissection of complex traits. Genetics 1998; 150:1699-1706. (Pubitemid 28555570)
43. Curran-Everett D. Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 2000; 279:R1-R8. (Pubitemid 30625409)
44. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125:279-284. (Pubitemid 33000466)
45. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36:S121-S127. (Pubitemid 35253472)
46. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004; 39:880-890. (Pubitemid 38428923)
47. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520. (Pubitemid 24166476)
48. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:S21-S29. (Pubitemid 35253460)
49. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-68.
50. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801. One of three different studies that shows the importance of common genetic variation in HCV disease. A substantial majority of the patients studied come from big HIV cohorts.
51. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104. One of three different studies that shows the importance of common genetic variation in HCV disease. A substantial majority of the patients studied come from big HIV cohorts.
52. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109. One of three different studies that shows the importance of common genetic variation in HCV disease. A substantial majority of the patients studied come from big HIV cohorts.
53. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77. (Pubitemid 36109115)
54. Zhang L, Jilg N, Shao RX, et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2010; in press.